This document includes fast facts on heaptitis B and how B hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus (HBV), which attacks liver cells and can lead to cirrhosis (scarring), liver failure, or liver cancer.
The liver is one of the body’s most important organs. It cleans toxins from the body and helps it digest food and absorb nutrients. The hepatitis B virus lives in the liver and can cause damage. It is important for people with hepatitis to understand their liver and how to protect it.
Liver Cancer Awareness Month Graphics for digital use.
This document discusses how an estimated 2.4 million people in the U.S. are living with hepatitis C infection, while up to 1.59 million people could be living with hepatitis B in the U.S. The need for expanded, standardized, and reliable viral hepatitis surveillance continues to impact public health efforts, resources, and response across the U.S. to this epidemic.
This document discusses how NASTAD strongly encourages 340B program administrators to incorporate health equity into their programs. Health equity means that everyone has a fair and just opportunity to be as healthy as possible and this requires removing obstacles to health such as structural racism and the intentional lack of social safety nets and investments that lead to poverty, unstable housing, food deserts, inadequate infrastructure and environmental injustices.
This document supports viral hepatitis program administrators in educating and preparing leadership to support 340B program implementation and partnerships.
The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years.
The recent emergence of the Coronavirus Disease (COVID-19) calls for enhanced cooperation between public health authorities, homeless service systems, and other partners at the local level. HUD strongly encourages CoCs to contact their local public health departments, Healthcare for the Homeless agencies, and other local health partners to ensure the unique needs and opportunities related to the homeless service system are incorporated in plans to prevent and respond to infectious diseases like COVID-19.
The newly launched Homelessness and Infectious Disease Questions Ask a Question (AAQ) desk assists homeless assistance providers, Continuums of Care (CoCs), and other partners with questions about preventing, mitigating, and responding to infectious diseases impacting people experiencing homelessness in their community. The AAQ desk is staffed by Technical Assistance (TA) providers from HUD's disaster response team who are well-versed in promising and emerging practices for infectious disease planning, mitigation, and response in homeless response systems.
The Unitaid-funded LONGEVITY project aims to develop long-acting formulations for malaria and latent tuberculosis (TB) prevention and a single-injection cure for hepatitis C virus (HCV) for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV.